There are 2789 resources available
543P - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Presenter: Mark Lythgoe
Session: ePoster Display
544P - A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
Presenter: Eunjung Lee
Session: ePoster Display
545P - First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part
Presenter: Toshihiko Doi
Session: ePoster Display
547P - Early pharmacokinetic data from a phase I study of SQ3370 in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform
Presenter: Vivek Subbiah
Session: ePoster Display
573P - Panorama of genomic RET alterations (GA) in the major subtypes of thyroid carcinomas (TC)
Presenter: Daniel Bowles
Session: ePoster Display
574P - Clinical impact of the GAPP score and SDHB negativity in patients with pheochromocytoma/paraganglioma
Presenter: Akihiro Ohmoto
Session: ePoster Display
575TiP - Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
Presenter: Enrique Grande
Session: ePoster Display
581P - Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1
Presenter: Fred Saad
Session: ePoster Display